PeLeMed

Executive Summary

PeLeMed is a private San Francisco-based biotech company founded in 2020, focused on developing personalized peptide-based immunotherapies for cancer and infectious diseases. The company's proprietary platform identifies patient-specific neoantigens and designs synthetic long peptides to elicit potent and durable T-cell responses. With an employee count of 50-200, PeLeMed operates in the preclinical stage, targeting a wide range of solid tumors and infectious pathogens. The approach aims to overcome the limitations of conventional checkpoint inhibitors by leveraging the patient's own immune system with high specificity. While the company has not disclosed total funding or valuation, its technology holds promise for improving outcomes in oncology and addressing urgent needs in infectious diseases, including potential pandemic preparedness applications. PeLeMed's progress is supported by its experienced team and a growing body of preclinical evidence. The company is expected to advance its lead candidate toward an Investigational New Drug (IND) application in the near term, with early clinical data anticipated to follow. Given the competitive landscape of personalized medicine, success will depend on demonstrating robust immunogenicity and tumor control in upcoming studies. PeLeMed's broad platform potential could attract partnership interest from larger pharmaceutical companies seeking novel immuno-oncology assets. The company represents a compelling opportunity in the precision immunotherapy space, albeit with typical early-stage risks.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Oncology Candidate60% success
• Q3 2026Publication of Preclinical Data in Peer-Reviewed Journal80% success
• H2 2026Series B Financing Round50% success